HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capability. As of 2020, we have an in-house scientific team of around 680 professionals, and a pipeline of 11 clinical stage drug candidates in clinical studies around the world. Our first three oncology drugs are now approved and marketed in China - ELUNATE® (fruquintinib capsules), SULANDA® (surufatinib capsules) and ORPATHYS® (savolitinib tablets) .
We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. We are expanding the geographic scope of our commercial operations to include the U.S. and Europe.
HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM : HCM ; HKEX : 13).